echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Electrocuting Cancer Cells - New "NanoKnife" Technology

    Electrocuting Cancer Cells - New "NanoKnife" Technology

    • Last Update: 2022-05-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    Prostate cancer affects 1 in 8 men, making it the most common cancer in men


    "We're about 50 years behind on breast cancer treatment," said Srinivas Vourganti, MD, a urologist at Rush University Medical Center


    Men with early-stage or low-risk prostate cancer can adopt a "watch and wait" strategy, which involves regular monitoring of the cancer but no immediate intervention to avoid a more aggressive approach


    "A lot of people want to find a middle ground between those two options," Vourganti said


    New NanoKnife Technology

    This "middle ground" is a new treatment from RUSH using NanoKnife, a tool for irreversible electroporation (IRE)


    Vourganti recently used the technique on one of his patients, John, who was diagnosed with prostate cancer in February 2021


    "It seemed like a good option, mostly because of the collateral damage that other things might have done," John said


    how it works

    The NanoKnife has four small probes inserted into the tumor, guided by ultrasound and magnetic resonance imaging (MRI)


    The surgery is performed under general anesthesia to ensure that the patient cannot move


    "People can go home that day," Vourganti said


    John underwent surgery in July 2021, which successfully destroyed cancer cells in his prostate


    "Because there are no side effects, I've returned to my normal life," John said


    NanoKnife Results

    Notably, 15 to 20 percent of prostate cancers recur after initial treatment, Vourganti said


    "We don't know if it will work for everyone," Vourganti said


    A clinical trial investigating NanoKnife in prostate cancer is enrolling patients at the Rush and Mayo Clinic


    John said he was pleased with the choice he made after consulting with Vourganti, stressing that Vourganti is committed to finding more options for prostate cancer patients
    .

    "He was passionate about what he was doing," John said
    .
    "He thinks it's a good idea to try something before doing something more extreme to help people
    .
    That doesn't mean it won't come back
    .
    But it's all relative, you know? I just Go with the flow
    .
    We have to do something
    .
    Let's make the best decision based on the options available
    .
    "



    Courtesy of Rush University Medical Center


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.